Online citations, reference lists, and bibliographies.
← Back to Search

Fibulin-3 As A Blood And Effusion Biomarker For Pleural Mesothelioma.

H. Pass, S. Levin, M. Harbut, J. Melamed, L. Chiriboga, J. Donington, M. Huflejt, M. Carbone, D. Chia, L. Goodglick, G. Goodman, M. Thornquist, G. Liu, M. D. de Perrot, M. Tsao, C. Goparaju
Published 2012 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
BACKGROUND New biomarkers are needed to detect pleural mesothelioma at an earlier stage and to individualize treatment strategies. We investigated whether fibulin-3 in plasma and pleural effusions could meet sensitivity and specificity criteria for a robust biomarker. METHODS We measured fibulin-3 levels in plasma (from 92 patients with mesothelioma, 136 asbestos-exposed persons without cancer, 93 patients with effusions not due to mesothelioma, and 43 healthy controls), effusions (from 74 patients with mesothelioma, 39 with benign effusions, and 54 with malignant effusions not due to mesothelioma), or both. A blinded validation was subsequently performed. Tumor tissue was examined for fibulin-3 by immunohistochemical analysis, and levels of fibulin-3 in plasma and effusions were measured with an enzyme-linked immunosorbent assay. RESULTS Plasma fibulin-3 levels did not vary according to age, sex, duration of asbestos exposure, or degree of radiographic changes and were significantly higher in patients with pleural mesothelioma (105±7 ng per milliliter in the Detroit cohort and 113±8 ng per milliliter in the New York cohort) than in asbestos-exposed persons without mesothelioma (14±1 ng per milliliter and 24±1 ng per milliliter, respectively; P<0.001). Effusion fibulin-3 levels were significantly higher in patients with pleural mesothelioma (694±37 ng per milliliter in the Detroit cohort and 636±92 ng per milliliter in the New York cohort) than in patients with effusions not due to mesothelioma (212±25 and 151±23 ng per milliliter, respectively; P<0.001). Fibulin-3 preferentially stained tumor cells in 26 of 26 samples. In an overall comparison of patients with and those without mesothelioma, the receiver-operating-characteristic curve for plasma fibulin-3 levels had a sensitivity of 96.7% and a specificity of 95.5% at a cutoff value of 52.8 ng of fibulin-3 per milliliter. In a comparison of patients with early-stage mesothelioma with asbestos-exposed persons, the sensitivity was 100% and the specificity was 94.1% at a cutoff value of 46.0 ng of fibulin-3 per milliliter. Blinded validation revealed an area under the curve of 0.87 for plasma specimens from 96 asbestos-exposed persons as compared with 48 patients with mesothelioma. CONCLUSIONS Plasma fibulin-3 levels can distinguish healthy persons with exposure to asbestos from patients with mesothelioma. In conjunction with effusion fibulin-3 levels, plasma fibulin-3 levels can further differentiate mesothelioma effusions from other malignant and benign effusions. (Funded by the Early Detection Research Network, National Institutes of Health, and others.).
This paper references
10.1093/CLINCHEM/39.4.561
Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine.
M. Zweig (1993)
10.1016/j.gene.2010.05.003
Molecular evolution of the fibulins: implications on the functionality of the elastic fibulins.
F. Segade (2010)
10.1167/IOVS.05-0070
Aberrant accumulation of fibulin-3 in the endoplasmic reticulum leads to activation of the unfolded protein response and VEGF expression.
C. Roybal (2005)
10.4149/NEO_2011_05_441
Downregulation of fibulin-3 gene by promoter methylation in colorectal cancer predicts adverse prognosis.
J. Tong (2011)
10.1158/0008-5472.CAN-04-4096
Fibulins 3 and 5 antagonize tumor angiogenesis in vivo.
A. Albig (2006)
10.1002/AJIM.4700220403
Use of death certificates in epidemiological studies, including occupational hazards: variations in discordance of different asbestos-associated diseases on best evidence ascertainment.
I. Selikoff (1992)
10.1186/1476-4598-10-123
EFEMP1 suppresses malignant glioma growth and exerts its action within the tumor extracellular compartment
Yuanjie Hu (2011)
10.1016/S0001-2998(78)80014-2
Basic principles of ROC analysis.
C. Metz (1978)
10.1002/path.2776
Fibulin‐3 is associated with tumour progression and a poor prognosis in nasopharyngeal carcinomas and inhibits cell migration and invasion via suppressed AKT activity
Chung-Feng Hwang (2010)
10.1148/RADIOLOGY.143.1.7063747
The meaning and use of the area under a receiver operating characteristic (ROC) curve.
J. Hanley (1982)
10.1245/s10434-009-0790-0
Epidermal Growth Factor-Containing Fibulin-Like Extracellular Matrix Protein 1, EFEMP1, a Novel Tumor-Suppressor Gene Detected in Hepatocellular Carcinoma Using Double Combination Array Analysis
Shuji Nomoto (2009)
10.1016/j.rmed.2010.10.010
Pleural effusion VEGF levels as a prognostic factor of malignant pleural mesothelioma.
N. Hirayama (2011)
10.1111/J.1432-1033.1996.0427H.X
Different susceptibilities of fibulin-1 and fibulin-2 to cleavage by matrix metalloproteinases and other tissue proteases.
T. Sasaki (1996)
10.1053/j.semtcvs.2009.06.007
Current status of screening for malignant pleural mesothelioma.
H. Pass (2009)
10.1200/JCO.2011.39.6671
Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis.
Kevin Hollevoet (2012)
10.3892/ijo.2011.1191
Fibulin-3 promoter methylation alters the invasive behavior of non-small cell lung cancer cell lines via MMP-7 and MMP-2 regulation.
E. Kim (2012)
The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982;143:29-36
JA Hanley (1982)
10.1158/1541-7786.MCR-08-0132
EFEMP1 Expression Promotes In vivo Tumor Growth in Human Pancreatic Adenocarcinoma
H. Seeliger (2009)
10.1016/S0945-053X(97)90021-4
Human fibulin-1D: molecular cloning, expression and similarity with S1-5 protein, a new member of the fibulin gene family.
H. Tran (1997)
10.1167/IOVS.05-1600
Maculopathy due to the R345W substitution in fibulin-3: distinct clinical features, disease variability, and extent of retinal dysfunction.
M. Michaelides (2006)
10.1056/nejmoa051185
Asbestos exposure, pleural mesothelioma, and serum osteopontin levels.
H. Pass (2005)
10.1002/ijc.24108
Decreased expression of angiogenesis antagonist EFEMP1 in sporadic breast cancer is caused by aberrant promoter methylation and points to an impact of EFEMP1 as molecular biomarker
A. Sadr-Nabavi (2009)
10.1016/j.exer.2009.09.018
Focus on molecules: fibulin-3 (EFEMP1).
Y. Zhang (2010)
10.1016/j.placenta.2009.01.007
Differential expression of fibulin family proteins in the para-cervical weak zone and other areas of human fetal membranes.
R. Moore (2009)
Imaging , Diagnosis , Prognosis EFEMP 1 as a Novel DNA Methylation Marker for Prostate Cancer : Array-Based DNA Methylation and Expression Profiling
Y. Kim (2011)
10.1111/j.1582-4934.2010.01019.x
Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from breast carcinoma in effusions
B. Davidson (2010)
10.1097/JTO.0b013e31819f2e0e
Screening for Malignant Pleural Mesothelioma and Lung Cancer in Individuals with a History of Asbestos Exposure
H. Roberts (2009)
10.1510/icvts.2010.250357
Vascular endothelial growth factor in pleural fluid for differential diagnosis of benign and malignant origin and its clinical applications.
A. Fiorelli (2011)
10.1158/1078-0432.CCR-10-2817
EFEMP1 as a Novel DNA Methylation Marker for Prostate Cancer: Array-Based DNA Methylation and Expression Profiling
Y. Kim (2011)
10.1074/jbc.M611029200
A Comparative Analysis of the Fibulin Protein Family
N. Kobayashi (2007)
10.1378/chest.108.4.1122
A proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest Group.
V. Rusch (1996)
10.1158/1078-0432.CCR-07-0015
Frequent Inactivation of RAMP2, EFEMP1 and Dutt1 in Lung Cancer by Promoter Hypermethylation
Wen Yue (2007)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1002/(SICI)1097-0274(199712)32:6<573::AID-AJIM1>3.0.CO;2-R
The CARET asbestos-exposed cohort: baseline characteristics and comparison to other asbestos-exposed cohorts.
S. Barnhart (1997)
10.1158/1078-0432.CCR-0607-3
Gene Expression Profiles Predict Survival and Progression of Pleural Mesothelioma
H. Pass (2004)
10.1158/1541-7786.MCR-09-0207
Fibulin-3 Is Uniquely Upregulated in Malignant Gliomas and Promotes Tumor Cell Motility and Invasion
B. Hu (2009)



This paper is referenced by
10.1038/bjc.2015.62
The South West Area Mesothelioma and Pemetrexed trial: a multicentre prospective observational study evaluating novel markers of chemotherapy response and prognostication
C. Hooper (2015)
10.3807/JOSK.2015.19.1.069
In vivo Optical Coherence Tomography Imaging of the Mesothelium Using Developed Window Models
Y. Ahn (2015)
10.1186/gb-2013-14-12-r137
Integrative DNA methylation and gene expression analysis in high-grade soft tissue sarcomas
M. Renner (2013)
10.1093/ejcts/ezaa158
ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma.
I. Opitz (2020)
10.1002/path.5203
A novel age‐related venous amyloidosis derived from EGF‐containing fibulin‐like extracellular matrix protein 1
M. Tasaki (2019)
10.1038/bjc.2015.286
Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis
M. Kirschner (2015)
10.1371/journal.pone.0078783
Overexpression of EFEMP1 Correlates with Tumor Progression and Poor Prognosis in Human Ovarian Carcinoma
J. Chen (2013)
10.1111/crj.12028
Asbestos and the lung in the 21st century: an update
Silvie Prazakova (2014)
10.1016/J.MEDCLI.2014.08.005
Contribución del análisis del líquido pleural al diagnóstico de los derrames pleurales
L. Ferreiro (2015)
10.1016/j.lungcan.2013.09.017
The degree of microRNA-34b/c methylation in serum-circulating DNA is associated with malignant pleural mesothelioma.
Takayuki Muraoka (2013)
10.1586/17476348.2013.838016
Advances in the management of pleural disease
J. Corcoran (2013)
10.18632/oncotarget.12474
Glycodelin is a potential novel follow-up biomarker for malignant pleural mesothelioma
M. Schneider (2016)
10.1093/carcin/bgz103
Biomarkers for malignant pleural mesothelioma: a meta-analysis.
Christina Gillezeau (2019)
10.1016/J.RMCLC.2015.06.010
ENFERMEDADES RESPIRATORIAS OCUPACIONALES
F. M. Salinas (2015)
10.4172/2153-0602.S2-001
Exploration of Biomarkers for Asbestos Exposure and Occurrence of Malignant Mesothelioma Based on the Immunological Effects of Asbestos
Hidenori Matsuzaki (2013)
10.5114/kitp.2017.72232
Malignant mesothelioma as a difficult interdisciplinary problem
W. Rokicki (2017)
Malignant Pleural Mesothelioma : Current Perspectives in Early Detection and Diagnosis
Attapon Cheepsattayakorn (2020)
10.1016/S1877-1203(13)70381-1
Est-il possible et utile de faire un diagnostic précoce du mésothéliome pleural malin en 2013 ?
Philippe Astoul (2013)
10.1371/journal.pone.0114483
Combination of MiR-103a-3p and Mesothelin Improves the Biomarker Performance of Malignant Mesothelioma Diagnosis
D. Weber (2014)
10.1016/j.chest.2016.12.004
Malignant Mesothelioma Biomarkers: From Discovery to Use in Clinical Practice for Diagnosis, Monitoring, Screening, and Treatment
J. Creaney (2017)
10.1002/9781118990957.CH18
Mesothelioma: Screening in the modern age
Joanna Sesti (2018)
10.1007/s13665-015-0106-8
Discovery of new biomarkers for malignant mesothelioma
J. Creaney (2015)
10.12688/f1000research.11646.1
Diagnostic approach to pleural diseases: new tricks for an old trade
F. Maldonado (2017)
Mesothelin in serum and pleural effusion in the diagnosis of malignant pleural mesothelioma with non-positive cytology.
M. C. Franceschini (2014)
YKL-40 and mesothelin in the blood of patients with malignant mesothelioma, lung cancer and asbestosis.
M. Corradi (2013)
10.5772/intechopen.91769
Predictive and Prognosis Factors of Clinical Utility in Mesothelioma
Rodríguez-Cid Jeronimo Rafael (2020)
Prasugrel versus Clopidogrel for Acute Coronary Syndromes
S. Schultz (2013)
10.1177/1753465816671697
Current best practice in the evaluation and management of malignant pleural effusions
S. Walker (2017)
10.1016/j.jtho.2016.04.028
Consensus Report of the 2015 Weinman International Conference on Mesothelioma
M. Carbone (2016)
10.21037/tlcr.2017.05.06
Diagnostic and prognostic biomarkers for malignant mesothelioma: an update.
Z. Chen (2017)
10.21037/jtd.2018.01.171
Treatment of malignant pleural mesothelioma: lessons learned and quo vadis?
S. Boeluekbas (2018)
10.2217/bmm-2017-0087
Comparison of statistical methods for detection of serum lipid biomarkers for mesothelioma and asbestos exposure.
Rengyi Xu (2017)
See more
Semantic Scholar Logo Some data provided by SemanticScholar